Search results
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease
Zacks via Yahoo Finance· 2 years agoThe FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was...
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
Reuters via Yahoo Finance· 4 months ago(Reuters) -AbbVie on Friday raised its 2027 forecast for sales of its immunology drugs Skyrizi and...
Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More
Zacks via Yahoo Finance· 9 months agoThe FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo...
2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade
Motley Fool via Yahoo Finance· 5 months agoNow that 2023 is firmly in the rearview, we can say without a doubt that it was a remarkable year...
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Motley Fool via Yahoo Finance· 2 weeks agoWall Street is feeling pretty good about AbbVie's (NYSE: ABBV) performance in 2024 so far. Louise...
AbbVie expects Botox to maintain market share as competition heats up
Reuters via Yahoo Finance· 5 months ago(Reuters) -AbbVie expects Botox's market share in the aesthetics space to remain strong even as...
2 High-Yield Healthcare Stocks to Buy With Both Hands and 1 to Avoid for Now
Motley Fool via Yahoo Finance· 4 months agoThere's one constant you can always rely on. Regardless of what's happening to the overall economy,...
There’s a New Weight-Loss Drug Called Zepbound. Really? Zepbound?
Slate via Yahoo News· 7 months agoThis week, the world simultaneously got yet another weight-loss drug and a reason to wonder why...
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
Benzinga via Yahoo Finance· 5 months agoAbbVie Inc (NYSE:ABBV) remains confident in Botox’s resilience in the aesthetics market, assured by...
AbbVie misses sales estimates as Botox, Juvederm face slowdown jitters
Reuters via Yahoo Finance· 2 years agoAbbVie Inc on Friday missed Wall Street estimates for quarterly sales, hurt by weaker-than-expected revenue from its popular facial filler Juvederm and blockbuster anti-wrinkle injection Botox ...